Get the Stockscreener App
161.84
4.72%
7.30
Charles River Laboratories International Inc stock is traded at $161.84, with a volume of 1.25M.
It is up +4.72% in the last 24 hours and down -0.93% over the past month.
Charles River Laboratories was founded in 1947 and is a leading provider of drug discovery and development services. The company's research model & services segment is the leading provider of animal models for laboratory testing, which breeds and delivers animal research models with specific genetic characteristics for preclinical studies around the world. The discovery & safety assessment segment includes services required to take a drug through the early development process, including discovery services. The manufacturing support segment includes microbial solutions, which provides in vitro (non-animal) testing products, biologics testing services, and avian vaccine services.
See More
Previous Close:
$154.54
Open:
$155.95
24h Volume:
1.25M
Relative Volume:
1.43
Market Cap:
$7.96B
Revenue:
$4.06B
Net Income/Loss:
$413.08M
P/E Ratio:
20.20
EPS:
8.01
Net Cash Flow:
$560.48M
1W Performance:
+3.29%
1M Performance:
-0.93%
6M Performance:
-0.72%
1Y Performance:
-19.61%
1-Day Range:
$154.79
$164.57
1-Week Range:
$154.43
$164.57
52-Week Range:
$91.86
$230.02
Charles River Laboratories International Inc Stock (CRL) Company Profile
Name
Charles River Laboratories International Inc
Sector
Industry
Phone
781-222-6000
Address
251 BALLARDVALE ST, WILMINGTON, MA
Compare CRL with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CRL
Charles River Laboratories International Inc
|
161.84 | 7.73B | 4.06B | 413.08M | 560.48M | 8.01 |
|
TMO
Thermo Fisher Scientific Inc
|
499.99 | 184.10B | 43.21B | 6.58B | 6.17B | 17.29 |
|
DHR
Danaher Corp
|
211.80 | 149.66B | 24.01B | 3.41B | 4.86B | 4.70 |
|
IDXX
Idexx Laboratories Inc
|
645.55 | 51.03B | 4.04B | 985.66M | 774.34M | 12.01 |
|
A
Agilent Technologies Inc
|
121.63 | 33.56B | 6.63B | 1.17B | 1.19B | 4.05 |
|
IQV
Iqvia Holdings Inc
|
191.15 | 32.73B | 15.70B | 1.24B | 2.01B | 6.91 |
Charles River Laboratories International Inc Stock (CRL) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-09-25 | Upgrade | Citigroup | Neutral → Buy |
| May-23-25 | Upgrade | Redburn Atlantic | Neutral → Buy |
| May-14-25 | Upgrade | TD Cowen | Hold → Buy |
| May-08-25 | Upgrade | Evercore ISI | In-line → Outperform |
| Mar-21-25 | Downgrade | Goldman | Buy → Neutral |
| Mar-04-25 | Upgrade | Citigroup | Sell → Neutral |
| Mar-03-25 | Upgrade | Redburn Atlantic | Sell → Neutral |
| Jan-22-25 | Downgrade | William Blair | Outperform → Mkt Perform |
| Jan-17-25 | Downgrade | UBS | Buy → Neutral |
| Nov-18-24 | Downgrade | CLSA | Hold → Underperform |
| Nov-07-24 | Upgrade | CLSA | Underperform → Hold |
| Oct-23-24 | Initiated | CLSA | Underperform |
| Oct-14-24 | Initiated | Redburn Atlantic | Sell |
| Oct-07-24 | Downgrade | Evercore ISI | Outperform → In-line |
| Oct-02-24 | Downgrade | BofA Securities | Buy → Neutral |
| Oct-01-24 | Downgrade | Citigroup | Neutral → Sell |
| Aug-08-24 | Downgrade | JP Morgan | Overweight → Neutral |
| Aug-08-24 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Jun-28-24 | Downgrade | Argus | Buy → Hold |
| Jun-07-24 | Initiated | Mizuho | Neutral |
| Jun-06-24 | Initiated | Goldman | Buy |
| Feb-15-24 | Downgrade | Guggenheim | Buy → Neutral |
| Sep-13-23 | Initiated | TD Cowen | Market Perform |
| Jul-10-23 | Downgrade | Citigroup | Buy → Neutral |
| Feb-23-23 | Upgrade | Guggenheim | Neutral → Buy |
| Jan-12-23 | Downgrade | Jefferies | Buy → Hold |
| Sep-30-22 | Upgrade | Jefferies | Hold → Buy |
| Aug-25-22 | Initiated | Credit Suisse | Outperform |
| Aug-04-22 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| May-24-22 | Initiated | Guggenheim | Neutral |
| Apr-25-22 | Downgrade | Jefferies | Buy → Hold |
| Apr-07-22 | Initiated | Stephens | Overweight |
| Feb-17-22 | Reiterated | BofA Securities | Buy |
| Feb-17-22 | Upgrade | Citigroup | Neutral → Buy |
| Feb-17-22 | Reiterated | Deutsche Bank | Buy |
| Feb-17-22 | Reiterated | Morgan Stanley | Overweight |
| Feb-17-22 | Reiterated | UBS | Buy |
| Aug-05-21 | Resumed | Credit Suisse | Neutral |
| Dec-16-20 | Downgrade | Citigroup | Buy → Neutral |
| Sep-10-20 | Upgrade | Jefferies | Hold → Buy |
| Jul-01-20 | Upgrade | BofA Securities | Neutral → Buy |
| May-13-20 | Upgrade | UBS | Neutral → Buy |
| Apr-21-20 | Downgrade | Jefferies | Buy → Hold |
| Mar-27-20 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Mar-02-20 | Initiated | Deutsche Bank | Buy |
| Feb-18-20 | Upgrade | Wolfe Research | Peer Perform → Outperform |
| Jan-10-20 | Upgrade | Goldman | Neutral → Buy |
| Jan-08-20 | Initiated | Wells Fargo | Overweight |
| Jan-07-20 | Initiated | Citigroup | Buy |
| Oct-18-19 | Downgrade | BofA/Merrill | Buy → Neutral |
| Jun-10-19 | Initiated | SVB Leerink | Outperform |
| Apr-30-19 | Resumed | Evercore ISI | Outperform |
| Dec-14-18 | Initiated | Deutsche Bank | Buy |
| Oct-09-18 | Initiated | UBS | Neutral |
| Aug-23-18 | Upgrade | Raymond James | Mkt Perform → Outperform |
| Jul-17-18 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Jun-15-18 | Upgrade | KeyBanc Capital Mkts | Sector Weight → Overweight |
| Feb-14-18 | Upgrade | SunTrust | Hold → Buy |
View All
Charles River Laboratories International Inc Stock (CRL) Latest News
Stock Analysis | Charles River Laboratories International OutlookA Weak Technical Profile But Strong Fundamentals - AInvest
Pharmaceutical company to expand Charleston County operations - Live 5 News
Healthcare firms see growing activist investor involvement in the past year - Reuters
Charles River Labs scales back Memphis project, slashes expected jobs - The Business Journals
Clinical Trial Biorepository and Archiving Solutions Market Size Expected to Attain USD 9.69 Billion by 2034 - GlobeNewswire Inc.
Earnings call transcript: Charles River Labs Q2 2025 beats EPS forecasts - Investing.com Canada
FRAUD AND MANIPULATION—1st Cir.: CEO’s reaction to macaque conspiracy was actionably misleading - VitalLaw.com
Huge proposed Memphis project downsizes by 500 jobs - The Business Journals
Charles River, LabCorp upgraded, Quest downgraded at Citi on valuation - MSN
Are Margin Pressures Shaping Charles River’s (CRL) Competitive Position Amid Stabilizing Revenue Guidance? - simplywall.st
Is Charles River Laboratories International Inc. exposed to currency risksPortfolio Gains Summary & Real-Time Volume Trigger Notifications - sundaytimes.kr
How Charles River Laboratories International Inc. stock reacts to Fed policy changesQuarterly Growth Report & Verified Swing Trading Watchlists - beatles.ru
Day 5 of Gains Streak for Charles River Laboratories International Stock with 5.3% Return (vs. -15% YTD) [8/15/2025] - Trefis
Charles River Laboratories International Inc. Stock Recovery Path — Analyst Breakdown2025 Market Sentiment & AI Enhanced Execution Alerts - sundaytimes.kr
Profitable Stocks to Watch: Dole, Charles River Laboratories, and LegalZoom - AInvest
Charles River Laboratories International Inc. Recovery Linked to Earnings Surprise2025 Analyst Calls & Real-Time Market Sentiment Alerts - sundaytimes.kr
Why Charles River Laboratories International Inc. stock attracts strong analyst attentionJuly 2025 Technicals & Weekly High Conviction Trade Ideas - sisa-n.com
What is Charles River Laboratories International Inc. s 5 year growth outlookJuly 2025 Final Week & Accurate Intraday Trading Signals - sundaytimes.kr
Custom Dashboard Highlights Charles River Laboratories International Inc. Price MomentumEarnings Recap Summary & Technical Entry and Exit Tips - 선데이타임즈
5 Revealing Analyst Questions From Charles River Laboratories’s Q2 Earnings Call - Yahoo Finance
Do Charles River (CRL) Earnings Trends Reveal Shifting Priorities in Its Advanced Therapeutics Ambitions? - simplywall.st
Centene, RadNet, Evolent Health, Illumina, and Charles River Laboratories Shares Are Soaring, What You Need To Know - Yahoo Finance
CRL Stock Gains on Q2 Earnings and Revenue Beat, Raises '25 View - MSN
Interpreting Charles River (CRL) International Revenue Trends - Yahoo Finance
Charles River Labs: Buy Rating and $179 Price Target Amidst Stability and Value Creation Potential - AInvest
Charles River Laboratories Q2 2025 Earnings Call Transcript Summary - AInvest
Charles River Laboratories International Inc's Q2 2025 Financials and Strategic Direction: A SWOT Analysis - AInvest
Charles River Laboratories Reports Q2 2025 Earnings - The Globe and Mail
Charles River Laboratories International Inc. stock underperforms Wednesday when compared to competitors - MSN
Charles River Laboratories International 2025 Q2 Earnings Misses Targets as Net Income Drops 44% - AInvest
Charles River Laboratories International, Inc. (NYSE:CRL) Q2 2025 Earnings Call Transcript - Insider Monkey
Charles River Laboratories International Second Quarter 2025 Earnings: Revenues Beat Expectations, EPS Lags - Yahoo Finance
Charles River Laboratories Q2 2025 Earnings Preview - MSN
Charles River Laboratories International Q2 2025 Earnings Call Transcript - MarketBeat
Charles River Laboratories International 2025 Q2 Earnings Beats Expectations as Net Income Drops 44.1% - AInvest
Charles River: Q2 Earnings Snapshot - Milford Mirror
Charles River Labs Reports Mixed Q2 Earnings Call - TipRanks
Charles River Laboratories Shares Drop 10.25% Despite 49.73% Volume Surge Ranking 339th in Market Activity as Order Cancellations Weigh on Investor Sentiment - AInvest
Charles River (CRL) Q2 EPS Jumps 11% - The Globe and Mail
Charles River Labs stock price target raised to $175 by BofA Securities - Investing.com India
Charles River Laboratories Q2 2025 Earnings Call Transcript Review - AInvest
Charles River Sees Limited Impact From NIH Cuts, Tariffs, Drug Pricing - Benzinga
Charles River: Margin Fears Outweigh Solid Q2 (NYSE:CRL) - Seeking Alpha
Charles River Labs cleared in DOJ monkey investigation, provides strategic review update - The Business Journals
Deutsche Bank Adjusts Price Target on Charles River Laboratories International to $185 From $180 - MarketScreener
Charles River Laboratories (CRL) Q2 Earnings and Revenues Surpass Estimates - sharewise.com
Charles River (CRL) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates - Yahoo Finance
Charles River Laboratories International Inc Stock (CRL) Financials Data
Revenue
Net Income
Cash Flow
EPS
4.05%
1.90%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):